Editorial: Community series in post-translational modifications of proteins in cancer immunity and immunotherapy, volume II

Editorial: Community series in post-translational modifications of proteins in cancer immunity and immunotherapy, volume II

Bibliographic Details
Main Authors:	Naoe Taira Nihira, Tomohiko Ohta, Zichuan Liu, Xiangpeng Dai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-09-01
Series:	Frontiers in Immunology
Subjects:	post-translational modifications PD-1 PD-L1 tumorigenesis cancer metabolisms
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1289016/full

Similar Items

Editorial: Post-translational modifications of proteins in cancer immunity and immunotherapy
by: Xiangpeng Dai, et al.
Published: (2022-08-01)

Editorial: Community series in post-translational modifications of proteins in cancer immunity and immunotherapy, volume III
by: Xuejing Zhao, et al.
Published: (2024-12-01)

Anti-Tumor Potential of Post-Translational Modifications of PD-1
by: Xiaoming Xi, et al.
Published: (2024-03-01)

Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
by: Yao Jiang, et al.
Published: (2023-06-01)

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways
by: Rong Wang, et al.
Published: (2024-04-01)

PD-L1 is upregulated in CD163+ tonsillar macrophages from children undergoing EBV primary infection
by: Agustina Moyano, et al.
Published: (2022-11-01)

A platinum@polymer-catechol nanobraker enables radio-immunotherapy for crippling melanoma tumorigenesis, angiogenesis, and radioresistance
by: Wenxi Li, et al.
Published: (2023-04-01)

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
by: Peng Ding, et al.
Published: (2023-05-01)

Intestinal microbiota: a new force in cancer immunotherapy
by: Zhujiang Dai, et al.
Published: (2020-06-01)

Next‐generation Gene Silencers for Cancer Immunotherapy
by: Ng, Aik Seng
Published: (2017)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
by: Ruby Dhar, et al.
Published: (2023-04-01)

Assays for predicting and monitoring responses to lung cancer immunotherapy
by: Cristina Teixidó, et al.
Published: (2015-06-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Post-translational modifications of proteins : tools for functional proteomics /
by: Kannicht, Christoph
Published: (2008)

Modern possibilities of using immunotherapy in the treatment of cervical cancer
by: A. V. Tarasova, et al.
Published: (2021-09-01)

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
by: Luyao Wang, et al.
Published: (2023-07-01)

Immunotherapies for advanced hepatocellular carcinoma
by: Li-Yang Sun, et al.
Published: (2023-03-01)

How HP1 Post-Translational Modifications Regulate Heterochromatin Formation and Maintenance
by: Raquel Sales-Gil, et al.
Published: (2020-06-01)

Mechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy
by: Yang Xicheng
Published: (2022-01-01)

Targeting STING signaling for the optimal cancer immunotherapy
by: Yan Xu, et al.
Published: (2024-10-01)

Immunology and immunotherapy in the complex treatment of malignant tumors
by: V. F. Semiglazov, et al.
Published: (2021-04-01)

Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
by: Chong Feng, et al.
Published: (2023-07-01)

Advances in post-translational modifications of proteins and cancer immunotherapy
by: Yanqing Li, et al.
Published: (2023-08-01)

Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy
by: Rhoanne C McPherson, et al.
Published: (2014-12-01)

Biomarkers for immunotherapy in bladder cancer: a moving target
by: David H. Aggen, et al.
Published: (2017-11-01)

The Role of Immunotherapy in Pancreatic Cancer
by: Reetu Mukherji, et al.
Published: (2022-09-01)

Biomarkers for immunotherapy in esophageal cancer
by: Xuelian Wang, et al.
Published: (2023-05-01)

Immunology and immunotherapy in breast cancer
by: Vladimir Semiglazov, et al.
Published: (2022-05-01)

Current insight into the regulation of PD-L1 in cancer
by: Zhuandi Liu, et al.
Published: (2022-07-01)

Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study
by: Luigi Liguori, et al.
Published: (2024-11-01)

Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy
by: Xinran Gao, et al.
Published: (2024-03-01)

Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy
by: Jair Bar, et al.
Published: (2024-02-01)

Novel nanotherapeutics for cancer immunotherapy by albumin nanoparticles functionalized with PD-1 and PD-L1 aptamers
by: Qiping Jiang, et al.
Published: (2024-01-01)

Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art
by: Nicoletta Provinciali, et al.
Published: (2022-12-01)

Immunometabolic Markers in a Small Patient Cohort Undergoing Immunotherapy
by: Joshua Hofbauer, et al.
Published: (2022-05-01)

Post-Translational Modifications and Diabetes
by: Chiranjeev Sharma, et al.
Published: (2024-03-01)

Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy
by: Terufumi Kubo, et al.
Published: (2021-07-01)

Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies
by: Valentina B. Stevenson, et al.
Published: (2023-01-01)

Pseudoprogression in patients on immunotherapy
by: D. I. Yudin, et al.
Published: (2019-06-01)